Clinical Research Directory

Inclusion Criteria: * Subjects aged ≥ 18 years. * Subjects with symptom onset up to 24 hours. * Isolated primary demonstrated occlusion in a distal medium vessel (Non-dominant or distal M2-MCA segment, M3 or M4 segments of MCA, A2-A3 segments of ACA, P1, P2 and P3 segments of PCA) identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA). * Baseline NIHSS score ≥5 assessed before the procedure. * Pre-stroke mRS score ≤ 2. * Subjects with an ASPECTS score ≥ 6. * Informed consent obtained in accordance with the applicable country-specific regulations and as approved by the Ethics Committee (EC). Exclusion Criteria: * Subjects aged \< 18. * Suspected secondary DMVO. Suspicion or evidence of primary LVO whether it has been treated or not with fibrinolytic therapy or mechanical thrombectomy that subsequently develops a DMVO. * Baseline NIHSS score \<5 assessed before the procedure. * Pre-stroke mRS score \>2. * Subjects with an ASPECTS score \<6. * Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient. * Severe allergy to contrast media. * Subjects with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection. * Medical history of thrombocytopenia (Platelets \<100,000). * Subjects with tandem occlusions (evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery). * Subjects with occlusions in multiple vessels (e.g., MCA-M3 and ACA-A2), whether or not they undergo mechanical thrombectomy. * Subjects with cancer (with or without metastases) who have a life expectancy of less than 6 months. * Subjects participating in a clinical trial at the moment of the inclusion. * Subjects with pre-existing neurological or psychiatric illness that could confound the neurological or functional assessments.